Shepherding a new drug from concept to clinic requires scientific rigor at every stage. For small and large molecules, the journey through preclinical development begins with in vitro and in vivo assessment. This assessment includes a battery of absorption, distribution, metabolism, and excretion (ADME) studies followed by comprehensive toxicology. Assessing molecules using an established stepwise approach helps guide candidate selection and builds confidence ahead of regulatory submission. However, each stage must be carefully considered according to the unique characteristics of small or large molecules.
Step 1: Initial Compound Characterization
Successful drug development programs require deep knowledge of the molecules in question. Initial compound characterization involves a series of analytical and physicochemical assessments that prepare drug candidates for downstream work.
- Small molecules: Solubility, stability, lipophilicity, and ionization state are the most critical properties to assess, given their impact on a drug’s oral bioavailability and metabolism. These data inform early formulation strategies and help flag potential liabilities early.
- Large molecule: Drugs like monoclonal antibodies, peptides, or oligonucleotides present unique challenges. Scientists evaluate higher-order structure, aggregation potential, and immunogenicity risks to guide analytical strategy. This helps sponsors gather detailed insight, allowing them to make evidence-based decisions as they progress to ADME testing.
Step 2: In Vitro ADME Assessment
In vitro ADME testing is a critical early step in preclinical development. These rapid assays provide foundational data to guide medicinal chemistry, candidate selection, and predictions for downstream pharmacokinetics.
- Small molecules: Key assays include cell-based permeability (Caco-2, MDCK), metabolic stability in microsomes or hepatocytes, and plasma protein binding. Results reveal a drug’s ability to cross biological barriers, likelihood of metabolic degradation, and potential for drug–drug interaction (DDI).
- Large molecules: Testing for peptides, proteins, and antibodies is less standardized due to the complex structure of large molecules and their lack of validated protocols. Every assay must be custom-built for each drug, requiring significant resources for methodological innovation and follow-up research and development. Focus areas include serum stability, degradation patterns, and receptor-mediated disposition. Advanced ligand-binding and hybrid analytical assays can be used to consistently characterize these drugs. However, a tailored approach early on improves confidence for downstream in vivo and regulatory decisions.
Step 3: In Vivo ADME & Pharmacokinetics
In vivo ADME and pharmacokinetics studies translate laboratory findings into actionable data on systemic exposure and safety.
- Small molecules: In vivo assessment for small molecules examines oral bioavailability, distribution, metabolism, and excretion. These data inform dose selection, formulation adjustments, and safety signals. LC-MS/MS methods provide precise quantification at low concentrations.
- Large molecules: Species selection is critical due to immunogenicity and cross-reactivity differences. PK and biodistribution often show nonlinear kinetics and limited tissue penetration. Bioanalytical strategies like ELISA and hybrid LC-MS help characterize systemic exposure and target-mediated disposition. These data shape the initial design of toxicology studies in the next phase.
Step 4: Moving Toward Toxicology Studies
As ADME data accumulate, the transition to toxicology becomes pivotal in the preclinical drug development journey. This phase integrates ADME profiles to refine dose selection, identify safety margins, and shape study design for toxicity assessment.
- Small molecules: This stage focuses on the candidate’s metabolic pathways, potential off-target interactions, and specific organ or DDI risks. ADME results define organ systems and toxicity endpoints to investigate further.
- Large molecules: Special attention to immunogenicity, target-mediated effects, and protein aggregation risks is needed at this stage. Each of these characteristics impact future toxicology protocols for each drug candidate.
Step 5: Conducting Toxicology Studies
Toxicology studies are the final preclinical checkpoint for assessing safety before human trials. These tests build on ADME data and target exposure risks, guiding dosing and study design.
- Small molecules: Studies focus on acute, sub-chronic, and chronic toxicity as well as genetic and reproductive effects, and organ-specific risks. Species and regimens are selected based on ADME findings to highlight toxicity not apparent in early PK or in vitro results.
- Large molecules: Programs address immunotoxicity, target-specific effects, and the challenge of animal model relevance. Advanced bioanalytical tools and platform technologies help detect unique safety signals and integrate findings with ADME data for a holistic safety profile.
Step 6: Integrating Data for IND/CTA Submission
ADME and toxicology data provide the foundation for regulatory submissions like IND or CTA. Integrating these data into submission profiles clarifies human risk, justifies dosing, and supports safe trial initiation. A well-curated data package helps streamline regulatory review and eventual clinical advancement.
- Small molecules: Submissions highlight metabolite characterization, off-target risks, and drug–drug interactions, contextualizing safety findings with detailed ADME and toxicity results.
- Large molecules: Emphasis on immunogenicity, target engagement, and complex PK profiles, backed by tailored toxicology studies that address unique biologic risks.
A Final Word
A stepwise, data-driven approach to preclinical development, including robust ADME and toxicology studies, helps developers and sponsors make faster, more confident decisions. Small and large molecules have distinct needs at every phase, but each stage builds on the last to de-risk advancement and support safe clinical entry. As development challenges grow more complex, integrating preclinical studies is essential. Combining scientific rigor with strategic foresight gives new therapeutics the greatest chance of success. Developers and sponsors who lack the capacity or capability to conduct these assessments and navigating regulatory assessment in-house can build confidence by working with a lab testing partner.
